We first validated that TYR could catalyze the in situ generation of VHL-recruiting PROTACs to efficiently degrade TYR both in vitro and in vivo for curtailing melanin synthesis to effectively treat skin hyperpigmentation. The gene discussed is VHL; the disease is neoplasm.